Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.50 |
| ▸ | SLC6A7 | Q99884 | 6/20 | 0.41 |
| ▸ | MGLL | Q99685 | 7/20 | 0.41 |
| ▸ | ABL1 | P00519 | 4/20 | 0.39 |
| ▸ | BCR | P11274 | 4/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913138 | 0.87 | MGLL (0.54) | RBP4SLC6A7MGLLFAAH | |
| SCHEMBL14647954 | 0.87 | MGLL (0.54) | RBP4SLC6A7MGLLFAAH | |
| SCHEMBL14877286 | 0.85 | SLC6A7 (0.56) | RBP4SLC6A7MGLLABL1BCR | |
| SCHEMBL10175214 | 0.85 | SLC6A7 (0.56) | RBP4SLC6A7MGLLABL1BCR | |
| SCHEMBL10175842 | 0.83 | SLC6A7 (0.57) | RBP4SLC6A7MGLLABL1BCR | |
| SCHEMBL14877198 | 0.82 | MGLL (0.41) | SLC6A7MGLLHDAC4 | |
| SCHEMBL14877328 | 0.80 | SLC9A1 (0.44) | SLC6A7CYP3A4HDAC4 | |
| SCHEMBL14877213 | 0.80 | RBP4 (0.49) | RBP4SLC6A7MGLLFAAHCYP3A4 | |
| SCHEMBL14877287 | 0.79 | GPR52 (0.51) | RBP4SLC6A7MGLLABL1BCR | |
| SCHEMBL10175622 | 0.79 | GPR52 (0.51) | RBP4SLC6A7MGLLABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130244998-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-09-19 | — | — | US | disclosed |
| US-8513423-B2 | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20130102584-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA, NV (BE) | 2013-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102584-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, MGLL | RBP4 3666/4885SLC6A7 1612/4885MGLL 3/4885 |
| US-20130244998-A1 | PIPERIDIN-4-YL-AZETIDINE DIAMIDES AS MONOACYLGLCEROL LIPASE INHIBITORS | MGLL, PNLIP, LPL | RBP4 3301/4885SLC6A7 2321/4885MGLL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.